Transgene Bolsters Scientific Advisory Board with Two Top Cancer Immunotherapy Experts
Event summary
- Transgene appointed Prof. Antoine Italiano and Prof. Ignacio Melero to its Scientific Advisory Board on January 23, 2026.
- Italiano leads the Precision Medicine program at Gustave Roussy and has overseen 90+ clinical trials in the past five years.
- Melero is a pioneer in cancer immunotherapy and received an ERC Advanced Grant in 2024 for mRNA-based immunotherapy research.
- Both advisors bring expertise in immuno-oncology and precision medicine to support Transgene's myvac® platform and other viral vector-based cancer vaccines.
The big picture
Transgene's addition of two leading cancer immunotherapy experts to its Scientific Advisory Board underscores the company's focus on strengthening its scientific leadership as it advances its personalized neoantigen therapeutic vaccines. This move comes amid growing industry interest in precision oncology and the need for tailored immunotherapies. The appointments could enhance Transgene's ability to navigate complex clinical development pathways and secure regulatory approvals for its innovative cancer treatments.
What we're watching
- Clinical Development Pace
- How the advisors' expertise will accelerate Transgene's myvac® platform and other viral vector-based cancer vaccine candidates.
- Strategic Partnerships
- Whether Transgene can leverage these appointments to form new collaborations with top oncology institutions.
- Regulatory Approvals
- The pace at which Transgene can advance its clinical programs with the support of these high-profile advisors.
Related topics